Our annual HEPATOPAC® User Group Meeting has gone virtual! This event will showcase the latest applications for HEPATOPAC cultures. Researchers from industry and academia will present how they have used HEPATOPAC cultures to investigate the ADME-Tox profiles of drug candidates and assess efficacy of new drugs in their lead selection programs.
Join us for these presentations and discussions on how HEPATOPAC Technology is being used to advance drug discovery and development programs to:
• Learn about our newest product, HEPATOMUNE® Cultures, for inflammation studies
• Discover how your peers are using HEPATOPAC Technology
• Understand how High-Content Imaging (HCI) is used to evaluate hepatic response
• Explore how the technology is applied in liver disease (NAFLD) and infectious disease (HBV)research
• Uncover opportunities for collaboration and ideas that you can use in your research
Can We Buy You Lunch?
Since our event has transitioned to a virtual event, we would like to offer any registrants a $20, €20, UberEats voucher. When you fill out the registration form below select whether you'd like to receive our lunch voucher. The voucher will be sent 24 hours before the start of the event.
Dr. Kang is part of the Molecular and Investigative Toxicology group within
Safety Assessment & Laboratory Animal Resources at Merck & Co. Her current
work focuses on the development of
in vitro cellular models and
problem-solving tools to de-risk
drug-induced liver toxicity in early
Dr. Chan joined the Drug Metabolism group
at Boehringer Ingelheim Pharmaceuticals
(BI) in 2009 as a Senior Scientist specializing
in hepatocyte applications, and he spent his
first few years investigating HEPATOPAC,
a promising new technology from MIT. At BI. He currently leads a group of scientists with
a focused interest on improving clinical
drug-drug interaction predictions using
novel in vitro technologies.
Dr. Khetani received his dual BS degrees in electrical engineering and biomedical engineering from Marquette University,
and MS and PhD degrees in bioengineering from University of California at San Diego (UCSD). Dr. Khetani’s 48+ publications in journals such as Hepatology, Nature Biotechnology, and PNAS have been cited more than 3500 times with an h-index of 25. Lastly, Dr. Khetani’s research has been funded over the last 10 years via ~$4.5 Min grants from the NIH, NSF, DOD, FDA, and the NSF CAREER award.
Originally from France, Dr. Sarkis obtained his
Ph.D. at the Institute of Genetics & Development of Rennes-CNRS. He joined Moderna in 2017 and became a member of
the Biological Science department, leading
a group to better understand Lipid Nanoparticle (LNP) mechanism of uptake
and identify models that help us identifying
lead formulations for animal studies. List of papers can be found here.
Prior to joining BioIVT, Scott worked in a number of academic institutions in a
diverse set of biological areas spanning developmental biology, gene therapy, and virology, with a focus on hepatotropic
viruses. As the Director of Research and Development for hepatic products in the ADME-Tox division for BioIVT, he focuses
on both new product development as well as support of application development for our existing products.